This candidate is in preclinical stages of development currently for the treatment of Triple Negative Breast Cancer. We also expect to develop it subsequently for a variety of other EGFR+ malignancies such as Colorectal, Head and Neck, Glioblastoma, Ovarian, Astrocytoma. Highly proliferative triple-negative breast cancers (TNBCs) have enhanced angiogenesis that supports rapid growth and early metastases and have been found to have high levels of VEGF. This candidate either alone or in combination with chemotherapeutic agent or anti-VEGF drugs is expected to be highly effective in treatment of such cancers. Anti-EGFR-TAP in efficacious in both in vitro and in vivo, and more importantly it is highly differentiated from bevacizumab in inhibiting certain important vasculogenesis functionalities.
Anti-HER2-TAP was studied in preclinical animal models as a therapeutic candidate for HER2 positive breast cancer treatment. The fusion has shown excellent inhibition of tumor growth, and significantly improved survival of the tumor-containing animals. Because of A-TAP’s long half-life and increased bioavailability in vivo, we expect positive outcome of the Anti-Her2-TAP fusion in clinical environment. Given the current results, and its differentiation from bevacizumab as an anti-angiogenic and VM-blocker, Anti-Her2-TAP is expected to be developed as a “biobetter” biological drug for breast cancer. It is also being developed for ovarian cancer.
Disease is war with the laws of our being, and all war, as a great general has said, is hell.
--Lewis G. Janes